This mutational profile has been reported in recurrent gliomas and is frequently associated with secondary alterations in mismatch repair genes, such as MSH6 or MSH2, ultimately correlating with increased tumor aggressiveness and reduced responsiveness to standard therapies, including the Stupp protocol (14, 15). The gene discussed is MSH2; the disease is central nervous system cancer.